Stock Alert: Applied DNA Sciences Jumps 50% On Positive COVID-19 Vaccine Data

Shares of Applied DNA Sciences, Inc. (APDN) are surging more than 50 percent or $4.51 in Friday's morning trade at $13.50 after the company reported positive preclinical results from its LineaDNA vaccine candidates for COVID-19.

Friday, Applied DNA Sciences said that linear-DNA forms of COVID-19 vaccine candidates under development by its partner Takis Biotech and manufactured by the company yielded strong antibody and T-cell responses even at very low doses of linear DNA, raising the potential of effective dosing empowering global utility.

"We are pleased to report that all five LineaDNA vaccine candidates provoked seroconversion in mice with all animals producing IgG against the SARS-CoV-2 Spike Protein by Day 14 and significantly enhanced responses by Day 38," said Dr. James Hayward, president and CEO of Applied DNA.

The company said it looked forward to supporting further studies by Takis with a goal of entering human trials in early Autumn.

Applied DNA Sciences has traded in a range of $2.52 to 19.69 in the past 52 weeks.

For comments and feedback contact: editorial@rttnews.com

Business News

Invest in the Best Pharma Stocks by Subscribing to RTT Biotech Investor.
Editors Pick
Integrated energy company Chevron reported Friday that profit for the fourth quarter increased 25 percent from last year, reflecting 17 percent revenue growth amid higher realizations and higher margins on refined product sales. Adjusted earnings per share missed analysts' estimates, while quarterly revenues topped it. Reno, Nevada-based ZLINE Kitchen and Bath has expanded its recall of gas ranges citing serious risk of injury or death from carbon monoxide poisoning, the U.S. Consumer Product Safety Commission announced. The recall now includes about 30,000 units of ZLINE gas ranges, including about 28,000 units... The Food and Drug Administration's independent advisory committee unanimously recommended replacing the current original COVID vaccines used in the U.S. for primary shots with new bivalent omicron shots authorized as boosters, reports said. The committee also considered the proposal for annual COVID vaccination, however, didn't vote on it.
Follow RTT